To overcome the shortcomings of the current treatments for AAT deficiency, we have developed an AAV-mediated gene therapy strategy using an AAV8 gene transfer vector coding for an oxidant-resistant AAT (8/AVL). The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.